Executive Summary
Investment Thesis
The Bull Case. Dixon is the purest listed vehicle for India's electronics-manufacturing decade — the only Indian firm in the global top-20 EMS by revenue, 24 factories, 45–50% of India's smartphone assembly capacity, and a client roster (Samsung, Xiaomi, Motorola, Google, vivo, HP, Nokia, boAt) no domestic rival matches. FY26 delivered ₹48,873 Cr revenue (+26%), adjusted PAT ₹845 Cr (+20%), ROCE above 30% on an adjusted basis with a negative working-capital cycle and ₹700 Cr+ of free cash flow — an EMS converter that funds 50% growth internally. Three growth engines are now stacked: (1) the Vivo JV (51:49, PN3-approved Jul 8, 2026) adds 20–22M annual smartphones at scale — a ~60% capacity addition worth ~₹30,000 Cr revenue against FY26's ₹48,900 Cr, starting Q3 FY27; (2) backward integration — camera modules (Q Tech: 70M → 180–190M units), the HKC display JV (24M displays Phase 1, ₹5,500–6,000 Cr revenue potential at mid-teens margins), precision components — lifts value-addition toward 35% and margins by a guided 40–50bps; (3) policy — MPMS (₹62,500 Cr, 2.25–5% incentives + adders for domestic components and R&D, replacing expired PLI) and Semicon 2.0 (₹1.27 lakh Cr ecosystem). Add the option legs — IT hardware tripling to ₹4,000 Cr+, telecom to ₹7,500–8,000 Cr, Ismartu Africa exports, HMD, specialty EMS (aerospace/defence/medical) targeted at ₹3,000–4,000 Cr at "significantly higher margins," a server JV under exploration — and consensus 36–45% EPS CAGR through FY28 is a defensible base case.
The Bear Case. Price and promises. At ₹14,260 you pay ~102x trailing adjusted earnings for a 1.7%-net-margin converter whose customers set its fees — buyer power here is near-absolute: Motorola already moved 15% of its volume to a rival, and vivo's own JV stake means Dixon's biggest volume win is shared economics. The FY26 scorecard shows what happens when demand wobbles: management guided 40–42M smartphones in July 2025 and delivered 32–33M (−22%), guided 100–120bps of integration-led margin expansion and later trimmed it to 40–50bps; the stock halved from ₹18,471 to ₹9,600 as the memory-price supercycle crushed handset demand and PLI expired. Reported FY26 PAT (₹1,644 Cr) includes ₹693 Cr of one-off gains — the clean number is ₹845 Cr, and Q4 adjusted PAT fell 36% YoY. Promoter holding has dropped 6.3pp in five years to 28.7%, including Sunil Vachani's ₹2,221 Cr block sale at ₹13,301 in June 2025 — almost exactly today's price. A ₹1,380 Cr PLI receivable sits with the government. And the reverse math is demanding: to earn 15%/yr from here for three years at a 40x exit, Dixon needs FY29 EPS of ~₹542 — ₹3,290 Cr PAT, ~₹1.73 lakh Cr revenue at current margins, i.e. 3.5x FY26 revenue by FY29. That is the full MPMS dream executed flawlessly, with nothing left for disappointment.
Key risk to monitor. The Vivo JV ramp (production start guided December quarter FY27; 11M units in FY27) and Q2 FY27 smartphone volumes against the "high-teens QoQ growth" exit guidance. Also watch memory prices: they broke FY26 guidance once already and remain elevated.
Top Findings
Key Financial Metrics (FY26, consolidated)
Pillar Scores
| Business Quality3.5 / 5 — exceptional execution & capital velocity inside a structurally low-margin, customer-dominated model | Management3.5 / 5 — best-in-class builders; FY26 guidance misses and promoter selling cost half a point each | Industry4 / 5 — a policy-turbocharged decade (MPMS, ECMS, Semicon 2.0); forces still favor OEMs over assemblers | Valuation2 / 5 — at fair value only if the base case lands; option legs are the margin of safety, and options aren't safety |
StockAnalystPro Quality Score: 75 / 100 (quality-with-watch-items band; breakdown in Advanced Frameworks). The highest score this framework has issued — earned by cash conversion, returns and execution; capped by concentration, fee-taker economics and guidance wobble.
Business & Industry
What Dixon actually does
Dixon (est. 1993, Noida; listed 2017 at ₹1,766) is a contract electronics manufacturer: brands design and sell, Dixon builds. It earns a largely fixed per-unit conversion charge (plus design/ODM fees where it owns the design), which makes revenue a function of volume × ASP and profit a function of volume × fee — percentage margins are almost a distraction (a point management makes explicitly: memory-price inflation raises ASPs and revenue while Dixon's per-unit profit is unchanged, optically compressing margin %). 24 factories, 6 R&D centres; FY26 capex ₹1,058 Cr funded from internal accruals.
Segment lens (FY26)
| Segment | FY26 revenue | Character | Read |
|---|---|---|---|
| Mobile & EMS | ₹44,257 Cr (~91%) | Engine + concentration risk | 32–33M smartphones (incl. 4–4.5M exports); Samsung, Motorola (85% of its volumes), Xiaomi, Oppo, Realme, Transsion, Nokia (sole supplier), Google Pixel. Telecom inside this line grew ₹3,600→5,000 Cr. IT hardware ramping (₹1,386 Cr; HP, Acer, Lenovo ecosystem via Inventec JV). One segment is 91% of the company — the anchor and the exposure are the same line. |
| Consumer electronics & appliances | ₹4,318 Cr (~9%) | Steady, higher-margin | LED TVs, refrigerators (transition-hit in Q4), washing machines (11%+ EBITDA margins — the margin anchor), lighting now in the 50:50 Signify JV (~₹800–850 Cr, doubling target). |
| Components (emerging) | immaterial yet | The margin thesis | Camera modules (Q Tech), displays (HKC JV, 74:26), precision parts, SSDs from Q2 FY27. This is where EBITDA/unit is supposed to double by FY28. Not yet in the numbers — entirely in the price. |
Industry structure & the July 2026 policy stack
India is now the world's #2 phone manufacturer; smartphones are its single largest export category; electronics manufacturing is up 7x since FY15. The July 2026 cabinet added two schemes on top of ECMS: MPMS (₹62,500 Cr, FY27–31): 2.25–5% incentives on eligible sales, +1.5% domestic-component adder, +3% India-design adder — directly replacing the expired mobile PLI and rewarding exactly the backward integration Dixon has built (blended ~3.5–4% achievable per scheme math). Semicon 2.0 (₹1,27,500 Cr): fabs, ATMP/OSAT, design — indirect for Dixon today, optionality if it moves up the component stack. Dixon holds ECMS approvals across camera modules (Jan 2026), display modules (Mar 2026, HKC) and more — 75 total industry approvals worth ₹617bn investment have been cleared, which cuts both ways: policy feeds Dixon and funds its future competitors (Tata Electronics, Foxconn India, Kaynes, Syrma all expanding).
Cycle position: mid-cycle with a policy afterburner. Handset demand wobbled through FY26 (memory supercycle, +12–15% ASP inflation) and is recovering sequentially; the structural build-out (gigafactories of the electronics kind) is early. Dixon's own stock ran the full emotional cycle in nine months: ₹18,471 (Sep 2025) → ₹9,600 (Mar 2026) → ₹14,260 (now).
Value migration
Classification: Strong Inward — with a queue forming. Global electronics value is migrating to India (China+1, tariffs, policy), and within India from imports to local assembly to local components. Dixon sits at the head of the queue with scale incumbency. The check on euphoria: migration attracts capital — 75 ECMS approvals means the next five Dixons are being subsidized right now, and the OEMs will happily multi-source among them.
Financials
Six-year consolidated summary (₹ Cr)
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | 6,448 | 10,697 | 12,192 | 17,691 | 38,860 | 48,873 |
| EBITDA | 292 | 384 | 519 | 705 | 1,515 | 1,867 |
| OPM % | 4.5% | 3.6% | 4.3% | 4.0% | 3.9% | 3.8% |
| Other income (incl. exceptionals) | 1 | 4 | 4 | 32 | 497 | 734 |
| Reported net profit | 160 | 190 | 255 | 375 | 1,233 | 1,644 |
| Adjusted PAT (after MI, ex-one-offs) | ~160 | ~190 | ~255 | 368 | 706 | 845 |
| Adjusted EPS (₹) | 27 | 32 | 43 | 61 | 117 | ~139 |
| Operating cash flow | 170 | 273 | 726 | 584 | 1,150 | 1,782 |
| Free cash flow | 2 | −145 | 276 | 16 | 254 | 724 |
| Borrowings / Net worth | 295 / 738 | 667 / 997 | 453 / 1,285 | 489 / 1,695 | 671 / 3,010 | 994 / 4,677 |
One-off health warning: FY25–26 reported PAT includes large exceptional gains (₹460 Cr FY25; ₹693 Cr FY26 — stake-sale/fair-value gains incl. Aditya Infotech). Every multiple in this report uses adjusted PAT (₹845 Cr FY26) unless stated. Screener-style "PE 60x" understates what you're actually paying by ~40%.
The 19-metric screen
| # | Metric | Value | Threshold | Verdict | Context |
|---|---|---|---|---|---|
| 1 | Sales CAGR 3Y / 5Y | 59% / 50% | >12% | Exceptional | mobile scale-up + Ismartu consolidation |
| 2 | Adj PAT CAGR 2Y / 5Y | 52% / ~40% | ≥ sales | Pass | profit compounding with revenue, unusually for EMS |
| 3 | EBITDA margin trend | 4.5% → 3.8% | Rising | Context | fixed-fee model: falling % ≠ falling per-unit profit; ASP inflation dilutes the ratio |
| 4 | Net margin (adj) | 1.7% | Stable+ | Thin by design | velocity economics — see DuPont |
| 5 | ROE (adj) | ~23% | >15% | Pass | reported 35.5% inflated by one-offs |
| 6 | ROCE (adj) | ~31% | >15% | Pass | reported 42%; brokers' adj 27–33% |
| 7 | ROIC | ~27% | >WACC 11% | Pass | core NOPAT ₹1,196 Cr on ~₹4,430 Cr invested capital |
| 8 | Incremental ROIC (FY21→26) | ~29% | >15% | Pass | ₹3,500 Cr new capital → ₹1,000 Cr new NOPAT — elite deployment |
| 9 | OCF/PAT (FY26 / 5Y cum.) | 1.08x / 1.22x | >1.0x | Pass | cash exceeds even the one-off-inflated PAT |
| 10 | FCF | +₹724 Cr | Positive | Pass | positive while growing 26% and capexing ₹1,058 Cr |
| 11 | D/E + interest cover | 0.21x / ~11x | <0.5x / >4x | Pass | net cash including investments |
| 12 | Cash conversion cycle | −7 days | <90 | Elite | suppliers + customers fund the growth |
| 13 | Receivables vs sales growth | 49d vs 65d | ≈ sales | Pass | debtor days fell in a +26% year |
| 14 | Inventory vs sales growth | 31d vs 41d | ≈ sales | Pass | leanest in five years |
| 15 | Fixed asset turnover | 11.7x | >2x | Pass | the core Dixon skill — sweating assets |
| 16 | Working capital days | −1 | <90 | Pass | payables 86d are trade-normal, not stretched |
| 17 | Buffett $1 test (5Y) | ~20x | >1x | Pass | Δmcap ₹67,200 Cr on ~₹3,300 Cr retained — and unlike most 20x readings, backed by 50% earnings CAGR |
| 18 | Asset-based floor value | ₹380/sh | — | 2.7% of CMP | 97% of the price is future earnings — the cost of buying velocity |
| 19 | Self-sustainable growth | ~22% | ≥ actual | Pass | FY26 asset growth 14% — fully self-funded |
Beneish M-Score signals (FY25 → FY26)
| Signal | Value | Threshold | Verdict | Commentary |
|---|---|---|---|---|
| DSRI (receivables index) | 0.75 | <1.1 | Pass | receivables tightened against sales |
| GMI (margin index) | ~1.03 | <1.0 | Benign | ASP-inflation optics, disclosed and explained |
| AQI (asset quality) | ~1.05 | <1.1 | Pass | growth is plant + CWIP (₹571 Cr) + JV investments, not soft assets; goodwill ₹580 Cr from Ismartu noted |
| SGI (sales growth) | 1.26 | <1.4 | Pass | fast but controls holding (see WC metrics) |
| Accruals / total assets | −0.7% | <5% | Pass | cash-backed earnings |
Earnings-quality verdict: 5/5 pass on the operating business. The only quality adjustment the reader must make is stripping the disclosed one-off gains from reported PAT — done throughout this report.
Capital allocation, 5 years (FY22–26)
| Source / use | ₹ Cr (approx.) | Comment |
|---|---|---|
| Cumulative operating cash flow | +4,515 | self-generated |
| Cumulative capex | ~−3,090 | 24 plants, camera/display capacity, IT lines |
| JV/strategic investments & acquisitions | ~−1,000 | Ismartu, HKC display, Q Tech, Rexxam, Signify, Inventec, Longcheer — a JV web that embeds customers and technology partners into Dixon's capital base |
| Net new borrowings | +327 | trivial vs scale; net cash position |
| Dividends | ~−250 | payout 4–8% — right call at 29% incremental ROIC |
Capital allocation grade: A−. ₹3,500 Cr deployed at ~29% incremental returns, funded internally, with the JV structure cleverly converting customers (vivo, HKC, Morita-style partners) into co-investors. The minus: minority leakage is growing (MI ₹206 Cr FY26, heading to ₹350–560 Cr by FY28 per brokers as JV-heavy revenue scales) — shareholders own less of each new rupee than the consolidated line suggests.
Moat & Advantage
Porter's Five Forces
| Force | Intensity | Evidence (named) | How Dixon neutralizes it — or doesn't |
|---|---|---|---|
| Buyer power (OEM brands) | Very High | Samsung, Xiaomi, Motorola, vivo set fixed conversion fees and can re-source: Motorola already shifted 15% of volumes to a rival; Oppo/Xiaomi/Transsion all cut CY26 global guidance 15–35%, passing demand risk straight through to Dixon's volumes. | Partially: JV structures (vivo 49%, Longcheer) make leaving costlier; component integration (camera/display) embeds Dixon deeper in the BoM; sole-supplier positions (Nokia) in niches. The fee-taker position itself is unchangeable. |
| Competitive rivalry | High | Foxconn & Tata Electronics (iPhone ecosystem, expanding Android ambitions), Kaynes, Syrma, Amber, PGEL domestically; Longcheer/Huaqin ODM globally. 75 ECMS approvals are funding rivals' capacity right now. | Scale (45–50% of India smartphone assembly), 30-year OEM relationships, fastest execution in the industry — a real but perishable lead. |
| Supplier power | Medium-High | Memory/semiconductor pricing (AI supercycle) drove 12–15% ASP inflation and crushed FY26 handset demand; displays/camera modules were import-dependent (China/Taiwan). | Directly attacked: HKC display JV, Q Tech camera JV, SSD line, Longcheer — Dixon is vertically integrating into its own supplier base with ECMS money. The most strategically coherent thing the company does. |
| Threat of new entrants | Medium-High | Policy money lowers entry cost; global EMS majors keep expanding India footprints. | Speed + relationships + a decade of PLI/ECMS approvals already banked; but the moat is a head start, not a wall. |
| Threat of substitutes | Medium | OEM in-house manufacturing (Samsung's own Noida plant is the largest phone factory on earth); brands can re-import if tariffs/geopolitics shift. | Cost + policy make outsourcing-in-India structurally favored for now; Dixon's multi-category breadth hedges any single product's fate. |
Forces verdict: hostile on both ends of the value chain — powerful buyers, concentrated suppliers — with policy as the counterweight. This is why world-class EMS companies earn 2% margins and trade at 10–25x. Feeds the Industry pillar: 4/5 only because the policy stack and India migration are once-a-generation; structurally it's a 2.5.
Moat scorecard
| Moat source | Score /3 | Evidence |
|---|---|---|
| Cost advantages / scale | 3 | India's largest EMS; 11.7x fixed-asset turns; negative working capital; labor + policy cost position vs China now decisive. The core moat. |
| Switching costs | 2 | Qualification cycles, JV equity locks (vivo, Longcheer, HKC), component co-development — rising steadily from a low base; Motorola's partial exit shows the ceiling. |
| Intangibles / relationships / licenses | 2 | Only Indian firm in global top-20 EMS; PN3-cleared Chinese JVs (a regulatory asset few rivals possess); portfolio of PLI/ECMS/MPMS approvals. |
| Regulatory / policy barriers | 2 | Approval stack = subsidized cost position through FY31; but policy feeds entrants too. |
| Pricing power | 0 | Fee-taker. None, by construction. |
| Network effects | 0 | None. |
Total: 9/18 → solid Narrow moat — wider than any Indian EMS peer, far short of the OEMs it serves. Reconciliation with the forces: consistent — Dixon's advantages are execution-speed and scale inside a structure that hands economics to customers. Hidden asset: the JV/associate portfolio (Aditya Infotech 6.5% stake — in MOFSL's TP; Signify, Rexxam, Imagine/boAt) carries real value the consolidated P&L understates.
CAP analysis — ROCE vs WACC (~11%, stated estimate)
| Year | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ROCE % (reported) | 30 | 23 | 24 | 29 | 40 | 42 |
| Spread vs WACC | +19 | +12 | +13 | +18 | +29 | +31 |
Six straight years of double-digit positive spread, widening — genuine value creation at compounder quality (adjusted numbers shave ~8–10pp but keep the spread firmly positive). The CAP question isn't whether Dixon creates value — it's how long a fee-taker can keep a 20pp+ spread while its customers watch. The JV-ification of new capacity (sharing economics with vivo, HKC, Longcheer) is partly the answer and partly the dilution of it.
DuPont decomposition (FY26, adjusted)
| Net margin | × Asset turnover | × Leverage | = ROE |
|---|---|---|---|
| 1.7% | ~8.2x | ~1.6x | ~23% |
The purest velocity business this framework has scored: sub-2% margins spun at 8x asset turns with modest leverage. Strategy direction: component integration deliberately trades some turnover for margin (displays at "mid-teens" margins vs 3.8% blended) — if it works, ROE holds while the mix shifts toward differentiation. That transition is the entire FY27–28 story.
Earning Power Box
Quadrant: High current earning power / High-but-rationed runway. ROIC ~27% with a widening spread puts current earning power in the top decile; the runway (India electronics 3x by FY31 under MPMS targets) is vast but rationed by OEM allocation decisions and shared through JV structures. Verdict: a genuine compounder — the rare quadrant — whose price already knows it.
Management & Governance
Management assessment
Founder-chairman Sunil Vachani (started 1993 with ₹15 lakh borrowed and 15 employees making CRT TVs) and MD Atul Lall (with the company since inception) are, on execution evidence, the best manufacturing operators in Indian listed markets: 50% revenue CAGR for five years with negative working capital, 29% incremental ROIC, no equity dilution since 2021, and a JV craft (Morita-style partner embedding: vivo, HKC, Longcheer, Inventec, Signify, Rexxam) that keeps converting threats into co-investors. Disclosure is institutional-grade: detailed segment data on calls, candid admissions (management conceded it was "slow to enter high-margin industrial EMS" when an investor pressed concentration risk).
The FY26 record adds necessary skepticism: the volume guidance miss was large (below), the margin promise was halved, and the founder sold ₹2,221 Cr of stock in June 2025 at ₹13,301 — within 7% of today's price — before the guidance cuts landed. None of it is disqualifying; all of it calibrates how much weight the FY27 promises deserve.
Commitment vs delivery
| Promised | When | Outcome | Verdict |
|---|---|---|---|
| FY26 smartphone volumes 40–42M | Q1 FY26 call (Jul 2025) | 32–33M delivered (−22%) | Missed |
| FY27 smartphone volumes 60–65M | Q1 FY26 call | Reframed May 2026 to "~32M ex-Vivo, flat" + Vivo 11–13M + exports | Reset lower |
| Backward-integration margin lift 100–120bps | Jul 2025 | Trimmed to 40–50bps (FY27–28) by Q4 FY26 call | Halved |
| FY26 revenue growth ~25%+ | FY25 exit | +26% (₹48,873 Cr) delivered through a demand shock | Delivered |
| Vivo JV approval "very close" | Q4 FY26 call (May 2026) | PN3 approval Jul 8, 2026 | Delivered |
| Telecom scale-up | FY25–26 calls | ₹3,600 → ₹5,000 Cr; export radio order won | Delivered |
| Display JV approvals + trials Q3 FY27 | FY26 calls | PN3/ECMS approved (Mar 2026); trials on schedule so far | On track |
| FY27: ₹56,000 Cr ex-Vivo revenue; IT hardware 3x; telecom ₹7.5–8k Cr | May 2026 | Open — the promises this report's KPI table tracks | Open |
Ownership signals
| Date | Event | Signal |
|---|---|---|
| FY21→FY25 | Promoter drift 35.0% → 32.3% (small sales, ESOP dilution) | − |
| Jun 23, 2025 | Sunil Vachani sells 16.7 lakh shares @₹13,301 (~₹2,221 Cr); stake 32.3% → 29.0%; Motilal Oswal MF bought 14.5 lakh of it | − − price now within 7% of that level |
| FY26 | FII 21.8% → 18.3% (through the crash); DII 23.1% → 28.2% (absorbed everything); shareholders 3.76 → 4.70 lakh | institutional rotation, retail influx |
| Jul 2026 | No insider buying disclosed around the Vivo/MPMS rally | neutral — absence of buy-signal at the lows is itself information |
Pledge: zero — none ever. The promoter sale is the only ownership blemish, and its price is a useful marker: the founder cleared a tenth of his holding at effectively today's price.
16-point fraud screen
| # | Item | Status | Evidence |
|---|---|---|---|
| 1 | Regulatory action / governance history | Pass | Clean SEBI/exchange record |
| 2 | Opaque subsidiaries / structures | Concern | Not opaque, but complex: a dozen JVs/subsidiaries with different stakes (51–100%) makes consolidated numbers progressively less owned by shareholders; MI line growing fast |
| 3 | Inter-corporate loans without justification | Pass | None visible; investments are equity in operating JVs |
| 4 | Related-party transactions at non-arm's-length | Pass | RPTs are with JV partners (vivo, HKC) at commercial terms, disclosed |
| 5 | FCF < 0.8x profit for 3+ years | Pass | Cum. FCF positive; FY26 FCF 0.86x adj PAT |
| 6 | Rising debt despite excess cash | Pass | Net cash; borrowings trivial vs scale |
| 7 | Unexplained loans/advances | Concern | ₹1,380 Cr PLI receivable from the government, incl. a disputed "overflow" claim (~₹1,100 Cr receivable vs ₹730 Cr payable) pending resolution — sovereign counterparty, but real money in limbo |
| 8 | Fixed assets disproportionate to revenue | Pass | 11.7x FA turnover — the opposite problem |
| 9 | Depreciation < 3% of gross fixed assets | Pass | ₹393 Cr on ~₹3,700 Cr gross ≈ 10% |
| 10 | Dividend stopped suddenly | Pass | Raised: ₹10/share final FY26 |
| 11 | Auditor resignation / qualified opinions | Pass | None on record |
| 12 | Promoter pledge high or rising | Pass | Zero |
| 13 | Receivables growing faster than sales | Pass | Debtor days 65 → 49 |
| 14 | Frequent dilution / warrants to promoters | Pass | Share count 60→61M over 3 years (ESOPs only) |
| 15 | Flattering accounting / presentation | Concern | Reported PAT headline (₹1,644 Cr) is 2x the adjusted operating figure (₹845 Cr) two years running on one-off gains — disclosed, but every screener shows the flattered number |
| 16 | Contingent liabilities vs net worth | n/d | FY26 AR schedules pending at data date |
Verdict: 12 pass, 0 fail, 3 concern, 1 n/d. Governance is genuinely strong; the concerns are structural (JV complexity, one-off optics, government receivable), not conduct.
Advanced Frameworks
Buffett $1 test (FY21 → FY26)
Market cap added ~₹67,200 Cr on ~₹3,300 Cr retained: ≈20x. Unlike most extreme readings, this one is substantially earned — adjusted earnings compounded ~40–50% annually over the period — but roughly half the mcap creation is multiple expansion on the India-EMS narrative. The retained-earnings engine is real; the price attached to it is the debate.
Self-sustainable growth rate
SSGR = adj ROE ~23% × (1 − 0.04 payout) ≈ 22% vs FY26 asset growth 14%: Dixon grows inside its own cash generation — extraordinary for a company compounding revenue at 50%. This is the practical meaning of negative working capital: customers and suppliers finance the expansion, shareholders keep the returns. It also means the FY27 capex (~₹1,000 Cr) and even the Vivo JV ramp need no dilution — the last equity raise was 2021.
Asset-based floor value (₹ Cr)
| Component | Book | Haircut | Value |
|---|---|---|---|
| Current/other assets net of current liabilities | 13,412 − 13,491 | — | −79 |
| Fixed assets + CWIP (electronics plants, fast obsolescence) | 4,743 | 50% | 2,372 |
| Investments (JV stakes at book) | 1,007 | 0% | 1,007 |
| Less: borrowings | −994 | — | −994 |
| Floor equity ≈ ₹2,306 Cr → ₹380/share (2.7% of CMP) |
97% of the price is a claim on future earnings. For a company of this quality that is normal — but it removes any pretense that the downside is cushioned by assets. The cushion is the earnings engine itself; if it stalls, the stock has already shown its air-pocket (−48% in six months to March 2026).
The billionaire test (adapted)
Buy all of Dixon at EV ≈ ₹85,600 Cr, funded 50:50 at 9% debt cost: interest bill ₹3,850 Cr vs core EBITDA ₹1,867 Cr — the whole company cannot service half its own purchase price at current earnings. Even at FY28E EBITDA (₹3,480–3,490 Cr per brokers), equity ROE is negative. Translation: no rational acquirer could pay today's price for the current business; the price is only payable for the 2030 business. That's not automatically wrong — it is exactly what "growth stock" means — but the test quantifies how much future is prepaid.
StockAnalystPro Quality Score — 75/100
| Component | Score | Max | Driver |
|---|---|---|---|
| Growth quality | 13 | 15 | 50% CAGR, self-funded, order-book backed; demand proved volatile in FY26 |
| Profitability & returns | 12 | 15 | ROIC ~27%, iROIC ~29%, spread widening; absolute margins razor-thin |
| Earnings quality | 11 | 15 | 5/5 Beneish, OCF > PAT; one-off-inflated headline PAT costs points |
| Balance sheet | 9 | 10 | Net cash, −7 day cycle, 11x cover; PLI receivable noted |
| Moat | 8 | 15 | 9/18 narrow — scale/speed/policy, zero pricing power |
| Management & capital allocation | 11 | 15 | A− allocation, elite execution; FY26 guidance misses + founder sale |
| Governance & fraud screen | 11 | 15 | 0 fails; JV complexity and MI leakage are the deductions |
| Total | 75 | 100 | Band: 65–79, quality with watch-items — the framework's highest score to date |
Score vs price: a 75-quality business at a 46–56x forward multiple is the classic great-company/fully-priced-stock configuration. The Quality Score answers "should this be on the watchlist" (emphatically yes); the Valuation tab answers "does today's buyer get paid" (only if the option legs convert).
Valuation
Framework selection
Profitable compounder mid-transition — primary framework: forward PE on FY28 scenario earnings (adjusted, ex-one-offs), cross-checked with EV/EBITDA, a reverse-expectations calculation, and the two fresh sell-side models (MOFSL 9-Jul, Emkay 10-Jul) the user supplied. Trailing multiples are useless at 102x adjusted.
EMS growth: what's already in the price vs what's still free
| Growth driver | Status | Evidence & quantification |
|---|---|---|
| Vivo JV — 20–22M units at scale, ~₹30,000 Cr revenue opportunity, 11–13M units FY27 | PRICED IN | Both broker models rebuilt within 48h of approval: MOFSL bakes 13M/17M (FY27/28), Emkay 6.5M/18M with a +14%/+17% EPS upgrade. The +48% rally off March lows is this event (plus MPMS). Execution from Q3 FY27 is now the hurdle, not the hope. |
| MPMS (₹62,500 Cr) replacing expired PLI — 2.25–5% + adders | PRICED IN | The Jul 15–16 cabinet pop took the stock from ~₹12,500 to ₹14,260. Blended 3.5–4% incentive achievable per scheme math ≈ restores the PLI-expiry margin hole brokers had already modeled away. |
| Backward integration: camera 70→180–190M units, display JV ₹5,500–6,000 Cr potential, +40–50bps margin | MOSTLY IN | Emkay explicitly models component EBITDA ₹228 Cr FY27 → ₹536 Cr FY28; MOFSL expects it to "more than offset" PLI loss by FY28. Any slippage in the Q3 FY27 display trials hits numbers already printed. |
| IT hardware 3x (₹4,000 Cr+), telecom ₹7,500–8,000 Cr, lighting 2x | MOSTLY IN | Consensus FY27 revenue ₹65,000–70,000 Cr already assumes these segment guidances land. |
| PLI 2.0 / mobile-export push (+4–5M export units; industry roadmap to 35% of global production, $70B exports by FY31) | PARTLY FREE | Management calls it upside to guidance; brokers mention but don't fully model. Emkay: "Mobile PLI 2.0 the next catalyst likely to lead to further EPS upgrades." |
| Specialty EMS — aerospace, defence, medical, industrial (₹3,000–4,000 Cr at "significantly higher margins"), CEO-level hire + consulting partner engaged | FREE | Not in either broker model. At 2–3x company margins this is the highest-quality option on the sheet — and the segment where management admitted being late. |
| Server/data-centre JV; display Phase 2 (50–55M panels); Semicon 2.0 ecosystem pull; Ismartu Africa exports; HMD | FREE | Exploratory/early — pure optionality, zero consensus credit. |
Bottom line: the price has consumed the base case. At ₹14,260 (46–56x FY28E adj EPS), the Vivo JV, MPMS, and the first component wave are in the number. The un-modeled legs — specialty EMS, PLI 2.0 exports, servers, display Phase 2 — are what a buyer at today's price is actually underwriting. They are real, but they are options, and the stock has twice shown (Jan 2025, Dec 2025–Mar 2026) what a 30–48% drawdown looks like when the priced-in legs wobble.
What's priced in — the reverse math
To earn 15%/yr for 3 years from ₹14,260 with a still-generous 40x exit multiple, Dixon must print FY29 EPS ≈ ₹542 — PAT ~₹3,290 Cr, which at ~1.9% net margin requires ~₹1.73 lakh Cr revenue: 3.5x FY26, a 52% revenue CAGR for three more years. That is the full national-mission scenario (MPMS working, Vivo at scale, exports tripling, components delivering) executed without a stumble. A more sober 12% discount check: consensus base FY28 EPS ₹280 at a 50x exit gives ₹14,000 — i.e., the market price equals the base case discounted at roughly 0%. Everything has to go right just to hold the price; going right faster than consensus is what generates return.
3×3 scenario matrix — FY28 adjusted EPS × exit PE
| De-rated 35x | Median 50x | Premium 65x | |
|---|---|---|---|
| Bear — EPS ₹210 Vivo ramp slips 2+ qtrs; memory drag persists; components late | ₹7,350−48% | ₹10,500−26% | ₹13,650−4% |
| Base — EPS ₹280 consensus mid (MOFSL 257 / Emkay 307): Vivo 17–18M, components deliver | ₹9,800−31% | ₹14,000−2% | ₹18,200+28% |
| Bull — EPS ₹340 Vivo full-scale + PLI 2.0 exports + display Phase 2 + specialty EMS traction | ₹11,900−17% | ₹17,000+19% | ₹22,100+55% |
Weights: bear 25% / base 50% / bull 25%; PE bands 25/50/25. Weighted fair value ≈ ₹13,900 — CMP ₹14,260 is 3% above it. Five of nine cells sit below the current price. Broker targets (₹15,200–16,100) live between base-median and base-premium — they require the premium multiple to hold. The bear-de-rated cell (₹7,350) is not hypothetical: the stock traded at ₹9,600 four months ago.
Cross-checks
| Check | Value | Read |
|---|---|---|
| EV/EBITDA | 43x FY26 → 23–24x FY28E | Global EMS majors trade at 8–15x; the India premium is 2x the world's best operators |
| PE band vs own history | fwd PE ~35–110x range since 2021 | current ~50x FY28E is mid-band — neither euphoric (Dec 2024: ~90x fwd) nor washed out (Mar 2026: ~33x FY28E) |
| Broker DCFs | ₹15,200–16,100 | +7–13% upside — both explicitly "policy support to continue" assumptions |
| Asset floor | ₹380/share | 2.7% of CMP |
Risk cards
KPI tracking table — thesis-break thresholds
| KPI | Current | Base trajectory | Bear trajectory | Thesis breaks if… |
|---|---|---|---|---|
| Vivo JV production start | guided Dec qtr FY27 | on time | +1 qtr | slips past Q4 FY27 |
| Vivo FY27 volumes | 0 (pre-start) | 11–13M | 6–8M | <6M by FY27-end |
| Smartphone volumes ex-Vivo (FY27) | 32–33M FY26 | flat ~32M | 28–30M | <28M — second demand miss |
| FY27 revenue (ex-Vivo guide ₹56,000 Cr) | ₹48,873 Cr FY26 | +15–17% | +8–10% | <₹53,000 Cr run-rate by H1 |
| Display JV milestones | trials Q3 FY27 guided | mass prod. Q4 FY27 | +1–2 qtrs | mass production beyond FY27 |
| Adj EBITDA margin | 3.8% FY26 | 3.5–3.6% FY27 → 3.9–4.1% FY28 | <3.3% | <3.2% two consecutive quarters |
| Adj PAT quarterly run-rate | ~₹192 Cr Q4 FY26 | ₹230–280 Cr by H2 FY27 | ₹180–200 Cr | <₹180 Cr any quarter |
| PLI/MPMS receivable | ₹1,380 Cr | declining | flat | >₹1,800 Cr or dispute escalation |
| Promoter holding | 28.7% | stable | −1pp | another block sale >1% |
| FY28 consensus adj EPS | ₹257–307 | drifting up (PLI 2.0) | cuts to ₹230–250 | consensus <₹220 — removes the valuation floor |
Earnings Review
Management Consistency Check
Q1 FY26 (Jul 2025): "40–42M FY26; 60–65M FY27" → Q4 FY26 (May 2026): ~32–33M delivered; FY27 flat ex-Vivo. Missed −22%
Last five earnings calls
Q4 FY26 — May 12, 2026
FY26: revenue ₹48,893 Cr (+26%), EBITDA ex-exceptionals ₹1,887 Cr (+23%), adj PAT after MI ₹845 Cr (+20%); ROCE 44.8%, WC cycle −8 days, FCF ₹700 Cr+. Q4 itself was soft — revenue ₹10,520 Cr (~flat), adj PAT ₹192 Cr (−36% YoY) on PLI expiry, geopolitical jitters, and memory-cost inflation; smartphone volumes ~5.6M in Q4, 32–33M for the year. Final dividend ₹10.
Outlook (the densest guidance set of the year): FY27 revenue ~₹56,000 Cr ex-Vivo (+15–17%); mobile volumes flat ex-Vivo with Vivo adding 20–22M annualized if approved; IT hardware >₹4,000 Cr (3x); telecom ₹7,500–8,000 Cr; lighting ~₹1,700 Cr; camera modules ₹2,500 Cr; display trials Q3, mass production Q4 FY27; margin +40–50bps once components deploy; capex ~₹1,000 Cr; new specialty-EMS thrust (aerospace/defence/medical, ₹3,000–4,000 Cr ambition) with a CEO-level hire; server JV exploration. Sentiment — own business: Confident; sector: Positive, demand caveated.
Q3 FY26 — Jan 29, 2026
Revenue ₹10,678 Cr (+2% YoY — the demand shock quarter), EBITDA ₹421 Cr (+6%), reported PAT ₹287 Cr (+69%, flattered by ₹139 Cr other income; operating PAT ~₹148 Cr). Smartphone volumes 6.9M in Q3, 27M for 9M FY26 — the 40–42M full-year guide was already dead; Q4 guided 7–7.5M.
Outlook: PLI winddown acknowledged as margin headwind; backward-integration capex in ramp phase; Vivo JV approval flagged as the focal catalyst. Sentiment — own business: Defensive; sector: Cautious (memory prices, inventory rationalization). The stock made its lows six weeks later.
Q2 FY26 — Oct 17, 2025
Momentum still intact mid-year; the call's substance was strategic: component roadmap detailed, camera-module ECMS application advancing (approved Jan 2, 2026), display module JV structure with HKC being finalized, IT hardware and telecom ramps on track. Specific quarter financials were overshadowed weeks later by the demand deterioration. Sentiment — own business: Optimistic; sector: Positive. In hindsight the last unguarded call before the reset.
Q1 FY26 — Jul 2025
The blowout: revenue ₹12,838 Cr (+95%), PAT ₹280 Cr (+100%), Mobile & EMS ₹11,663 Cr (+125%, 91% of revenue). Management guided FY26 volumes of 40–42M units, FY27 ambition 60–65M, and 100–120bps of FY27 margin expansion from backward integration.
Outlook then: pure acceleration. What followed teaches this stock's central lesson: quarterly momentum extrapolates badly when your demand curve belongs to your customers. Sentiment — own business: Bullish; sector: Bullish.
Q4 FY25 — May 20, 2025
FY25 closed at ₹38,860 Cr (+120%, the Ismartu + mobile scale-up year); Q4 revenue ₹10,304 Cr (+120% YoY); smartphone volumes 28.3M for FY25; TWS 23.7M (+47%). Net-debt-free; FY26 capex guided ₹900–1,000 Cr (delivered ₹1,058 Cr); PLI expiry (Mar 2026) flagged early with backward integration positioned as the offset — the strategy narrative that still governs today.
Key quote
Watch items — next call (Q1 FY27, ~late Jul 2026)
- Q1 volume + pricing print vs the "high-teens QoQ volume growth + 12–15% pricing" exit guidance — MOFSL models +19% YoY revenue; a miss here on the first post-Vivo-approval call would be expensive at 50x.
- Vivo JV operational detail — site, capacity commissioning, December-quarter start confirmation, FY27 unit expectation (11M per the JV announcement math).
- Display trials + MPMS fine print — Q3 trial confirmation for the HKC JV, and Dixon's effective MPMS incentive rate once scheme guidelines publish; plus any movement on the ₹1,380 Cr PLI receivable.
Peer Comparison
Domestic EMS/electronics manufacturers plus the global EMS majors that define mature contract-manufacturing economics. Forward-earnings comparison where possible; note Dixon's trailing PE below uses adjusted EPS (one-offs stripped).
| Company | Mkt cap | Revenue (FY26/CY25) | Rev growth | ROCE | PE (adj. trailing) | EV/EBITDA |
|---|---|---|---|---|---|---|
| Dixon Technologies (DIXON) | ₹86,544 Cr | ₹48,873 Cr | +26% | ~31% adj | ~102x (46–56x FY28E) | ~43x |
| PG Electroplast (PGEL) — appliances EMS | ₹17,269 Cr | ~₹5,000 Cr | −10% (qtr) | 10.3% | 88x | n/d |
| Havells (branded, for contrast) | ₹74,520 Cr | ~₹22,000 Cr | +2% (qtr) | 24.9% | 44x | n/d |
| Kaynes / Syrma (high-mix EMS)* | n/d this data | smaller | 30–50% | low-teens | ~80–120x* | high |
| Hon Hai / Foxconn (2317.TW) — global #1 | ~$75B* | ~$215B | high-single | ~10% | ~12–14x* | ~6–8x* |
| Jabil (NYSE: JBL) — global #3 | ~$24B* | ~$29B | mid-single | ~25%+ | ~20–25x* | ~10–12x* |
*Indicative from public reporting (web); not TapeTide/Rallies-verified at data date — marked accordingly. Tata Electronics and Foxconn India, Dixon's most direct strategic rivals, are unlisted.
Peer-by-peer read
PGEL shows the India-EMS multiple is a sector phenomenon, not a Dixon anomaly — 88x trailing for an appliance-focused EMS with 10% ROCE and a shrinking quarter. Against that cohort Dixon is the cheap quality: triple the returns, 5x the scale, similar multiple. The entire Indian EMS chain trades on the 2031 national mission, exactly as the user's thread argued — Dixon is simply its largest and best expression.
Havells (a brand owner, not an EMS) makes the value-chain point: brands with pricing power earn 25% ROCE and trade at 44x; Dixon earns comparable returns without pricing power only via velocity. When component integration raises Dixon's value-add toward 35%, its economics migrate a step toward the Havells end — that migration is worth paying something for; the question is 50x-worth.
Foxconn is the gravity well: the world's dominant EMS — Apple's manufacturer, $215B revenue — trades at ~12–14x earnings. Jabil, arguably the world's best-run diversified EMS, ~20–25x. Dixon at 46–56x FY28E carries a 2–4x premium to the global ceiling. The premium is India's growth differential (Dixon grows 5–10x faster) and it's mathematically defensible for exactly as long as 30%+ EPS growth persists; the moment growth normalizes, Foxconn's multiple is the destination. That is the long-term de-rating glide every holder should price.
Premium/discount verdict
Premium earned on quality, full on price. Within India, Dixon is the highest-quality name in an expensive cohort — best returns, best balance sheet, best execution record — so its multiple is peer-justified. Against global peers it is the most expensive scaled EMS company on earth. Both statements are true; the resolution is the growth runway, which is why the KPI table (Valuation tab), not the peer table, is where this thesis lives or dies.